Review: PDF OnlyHereditary breast cancer translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendationsCorso, Giovannia,,b; Magnoni, FrancescaaAuthor Information aDivision of Breast Cancer Surgery, IEO, European Institute of Oncology, IRCCS bDepartment of Oncology and Haemato-Oncology, University of Milan, Milan, Italy Received 22 May 2020 Accepted 25 June 2020 Correspondence to Francesca Magnoni, MD, PhD, Division of Breast Cancer Surgery, European Institute of Oncology, IRCCS, Milan, Italy, Tel: +39 02 94371092; e-mail: [email protected] European Journal of Cancer Prevention: September 3, 2020 - Volume Publish Ahead of Print - Issue - doi: 10.1097/CEJ.0000000000000624 Buy PAP Metrics Abstract Scientific acquisitions concerning the risk of breast cancer in the context of hereditary breast cancer syndrome are constantly evolving: alongside the BRCA1 and BRCA2 mutations, further ones have been identified, also associated with malignancies in different sites. Therefore, management of these clinical conditions requires a multidisciplinary and shared approach, based on constantly updated guidelines. The recent Expert Panel Consensus about management of hereditary breast cancer, chaired by the Society of Surgical Oncology with the American Society of Clinical Oncology and the American Society of Radiation Oncology, based on the evidences obtained by a systematic review of the literature, delineate accurate and novel directions towards an appropriate surgical, radiation, and systemic therapy management of breast cancer patients with specific germline mutations. These recent recommendations will provide to physicians an updated and useful tool in treatment decision making of these patients in daily practice. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.